James H. Stanker
Net Worth
Last updated:
What is James H. Stanker net worth?
The estimated net worth of Mr. James H. Stanker is at least $445,065 as of 5 Aug 2022. He owns shares worth $7,565 as insider and has received compensation worth at least $437,500 in Processa Pharmaceuticals, Inc..
What is the salary of James H. Stanker?
Mr. James H. Stanker salary is $87,500 per year as Chief Financial Officer in Processa Pharmaceuticals, Inc..
How old is James H. Stanker?
Mr. James H. Stanker is 67 years old, born in 1958.
What stocks does James H. Stanker currently own?
As insider, Mr. James H. Stanker owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | Chief Financial Officer | 36,510 | $0.21 | $7,565 |
What does Processa Pharmaceuticals, Inc. do?
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
James H. Stanker insider trading
Processa Pharmaceuticals key executives
Processa Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. David Young Ph.D., Pharm.D. (72) Co-Founder, Chairman, Interim Chief Financial Officer & Chief Executive Officer
- Dr. Sian E. Bigora Ph.D., Pharm.D. (65) Co-Founder & Chief Devel. Officer
- Mr. James H. Stanker (67) Chief Financial Officer
- Mr. Patrick Lin (60) Co-Founder, Chief Bus. & Strategy Officer
- Mr. Robert Michael Floyd (69) Chief Operating Officer
- Ms. Wendy J. Guy (61) Co-Founder, Chief Admin. Officer & Corporation Sec.